Olaparib + Zytiga for Metastatic Castrate-Resistant Prostate Cancer | Learn About Clinical Trials скачать в хорошем качестве

Olaparib + Zytiga for Metastatic Castrate-Resistant Prostate Cancer | Learn About Clinical Trials

This study is active, but no longer recruiting Estimated Primary Completion Date: April 13, 2021 Estimated Study Completion Date: August 17, 2022 PCRI's Executive Director, Mark Scholz, MD, describes the olaparib plus Zytiga (NCT03732820) clinical trial of interest to men with advanced metastatic Lupron-resistant (a.k.a. castrate-resistant) prostate cancer. 0:20 Lynparza is a medicine that is currently FDA-approved for the treatment of ovarian cancer. There are reasons to believe that it is also effective at treating prostate cancer, especially in cases where the BRCA mutation is present. 0:37 In this trial, Lymparza will be given to men with castrate-resistant prostate cancer. That means that a man has been on a drug like Lupron, his testosterone is low, and the cancer has nevertheless began to progress. 1:11 Lynparza has been shown to be most effective in cases where the BRCA mutation is present; however, some studies have suggested that this medication can also be effective in prostate cancer even when that mutation is not present. 1:33 In this clinical trial, researchers are interested in seeing if adding Lynparza to Zytiga can improve outcomes. 1:48 Lynparza, even though its a pill, has side effects similar to chemotherapy (low blood count, fatigue) and so it is best reserved for those who have become resistant to Lupron. 2:17 This study is just evaluating Lynparza with Zytiga, but there are a number of other useful medications for people in this situation. Other second-generation hormone therapies like Xtandi, Nubeqa, and Erleada. Chemotherapies like Taxotere and Jevtana. And the immunotherapy Provenge. 2:43 In this trial of 700 men, one group will get Zytiga and a placebo, and a second group will get Zytiga plus Lynparza. The two groups will then be followed to see if the group taking Lynparza has better outcomes than those taking the placebo. Don’t know your stage? Take the quiz: Visit http://www.prostatecancerstaging.org To learn more about prostate cancer visit http://www.pcri.org To download the free Staging Guide visit http://www.pcri.org/prostate-cancer-s... Who we are: The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors. The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs. #ProstateCancer #Prostate #MarkScholzMD